India, Aug. 5 -- Shares of Y-mAbs Therapeutics, Inc. (YMAB) are up over 100% at $8.53, on news of the company getting acquired by SERB Pharmaceuticals for approximately $412 million.
Under the terms of the merger agreement, SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock for $8.60 per share. The offer price represents a premium of approximately 105% to Y-mAbs' closing share price on August 4, 2025, the last full trading day before the transaction announcement.
Y-mAbs' lead asset is DANYELZA, the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma - a rare and aggressive pediatric cancer.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-15681895...